In The Press November 26, 2020

Rare ED Texas Pharma Lawsuit May Be A Sign Of Things To Come For Biosimilars (Intellectual Asset Management)

Recent difficulties obtaining preliminary injunctions against biosimilars in the District of Delaware could see more patentees looking to other venues when filing BPCIA suits, especially against foreign defendants. These decisions show the kinds of issue that can prevent a reference product sponsor from getting a preliminary injunction comment Goodwin Intellectual Property Litigation partner Alexandra Valenti. Read the Intellectual Asset Management article here.